Bkv Infection clinical trials

Explore recruiting bkv infection clinical trials.

Recruiting bkv infection studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Bkv Infection trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Evaluation and promotion of specific adaptative immunity against polyomavirus (BKV) to prevent viral infection after kidney transplantation (BK-VAX project)

Spain

Therapeutic use (Phase IV) EU CTIS Study details

Intravenous Immunoglobulins for Prevention of BKV Viremia in Kidney Transplant Recipients According to BKV genotype-specific Neutralizing Antibody Titers at the day of transplantation: A Multicenter Study -BKANIG

France

Phase III and phase IV (Integrated) EU CTIS Study details

Multicentre, open-label, randomised, two-arm, parallel-group, superiority trial to assess bioavailability and practicability of two once-daily tacrolimus formulations, Envarsus® compared with Advagraf™, administered in kidney transplant recipients

Germany

Therapeutic use (Phase IV) EU CTIS Study details

Bkv Infection trials by city

Bkv Infection in Toronto Bkv Infection in Vancouver Bkv Infection in Montreal Bkv Infection in Calgary Bkv Infection in Edmonton Bkv Infection in Ottawa Bkv Infection in Winnipeg Bkv Infection in Quebec City Bkv Infection in Hamilton Bkv Infection in Kitchener Bkv Infection in London Bkv Infection in Halifax Bkv Infection in New York Bkv Infection in Los Angeles Bkv Infection in Chicago Bkv Infection in Houston

Bkv Infection clinical trials

Recruiting bkv infection studies right now

Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis

R-MVST Cells for Treatment of Viral Infections

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.

Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation.

Evaluation of Safety and Efficacy of Virus Specific T-Cell Administration in Pediatric Patients With Systemic Viral Infection Following Allogeneic Hematopoietic Stem Cell Transplantation.

R-MVST Cells for Treatment of Viral Infections in Children and Young Adults

Treatment of BK Virus Infection With CTL Cells in Immunocompromised Transplant Patients

Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients

Third Party Viral Specific T-cells (VSTs)

Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections

Donor-Derived Viral Specific T-cells (VSTs)

Also recruiting in Europe

Evaluation and promotion of specific adaptative immunity against polyomavirus (BKV) to prevent viral infection after kidney transplantation (BK-VAX project)

Intravenous Immunoglobulins for Prevention of BKV Viremia in Kidney Transplant Recipients According to BKV genotype-specific Neutralizing Antibody Titers at the day of transplantation: A Multicenter Study -BKANIG

Multicentre, open-label, randomised, two-arm, parallel-group, superiority trial to assess bioavailability and practicability of two once-daily tacrolimus formulations, Envarsus® compared with Advagraf™, administered in kidney transplant recipients

Bkv Infection trials by city

Other conditions